Expression of splicing factors in human ovarian cancer

被引:7
|
作者
Fischer, DC
Noack, K
Runnebaum, IB
Watermann, DO
Kieback, DG
Stamm, S
Stickeler, E
机构
[1] Univ Freiburg, Med Ctr, Dept Obstet & Gynecol, D-79106 Freiburg, Germany
[2] Univ Erlangen Nurnberg, Dept Biochem, D-91054 Erlangen, Germany
关键词
ovarian cancer; alternative splicing; SR proteins; Tra2; YB-1;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Alternative splicing represents an important nuclear mechanism in the post-transcriptional regulation of gene expression, which is frequently altered during tumorigenesis. Previously, we have described marked changes in alternative splicing of the CD44 gene in ovarian and breast cancer. In the latter one we described also a specific induction of splicing factors during tumor development. Now we have focussed our studies on the expression profiles of splicing factors, including classical SR proteins, Tra2 and YB-1 in physiological and malignant ovarian tissues by RT-PCR and Western blot analysis. We detected changed expression pattern with higher levels of phosphorylated 30 kDa SR proteins as well as relatively high concentrations of hyperphosphorylated Tra2 protein isoforms in ovarian cancer. RT-PCR analysis revealed a marked induction of SC35 and ASF/SF2 as well as mRNA levels in malignant ovarian tissue. These results suggest gene-specific alterations of expression rather than a general induction of the splicing machinery. Together with previously performed functional studies of CD44 splicing these findings implicate that altered expression profiles of SR proteins, Tra2B and YB-1 might be responsible for the known changes of alternative CD44 splicing in ovarian cancer.
引用
收藏
页码:1085 / 1090
页数:6
相关论文
共 50 条
  • [1] Expression of nuclear splicing factors in ovarian cancer: correlations
    Stickeler, E.
    Iborra, S.
    Jaeger, M.
    Watermann, D.
    Hirschfeld, M.
    Gitsch, G.
    zur Hausen, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Alterations in Expression Pattern of Splicing Factors in Epithelial Ovarian Cancer and its Clinical Impact
    Iborra, Severine
    Hirschfeld, Marc
    Jaeger, Markus
    zur Hausen, Axel
    Braicu, Iona
    Sehouli, Jalid
    Gitsch, Gerald
    Stickeler, Elmar
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (06) : 990 - 996
  • [3] Growth factors in human ovarian cancer
    Westermann, AM
    Beijnen, JH
    Moolenaar, WH
    Rodenhuis, S
    CANCER TREATMENT REVIEWS, 1997, 23 (02) : 113 - 131
  • [4] Splicing factors and the role of Navitoclax in drug-resistant ovarian cancer
    Coley, Helen M.
    Lattanzio, Laura
    Garrone, Ornella
    Merlano, Marco
    Vivenza, Daniela
    Lo Nigro, Cristiana
    Syed, Nelofer
    Thompson, Alistair
    Rao, Bhavya
    Crook, Tim
    CANCER RESEARCH, 2017, 77
  • [5] Expression of epithelial splicing regulatory protein 1 and 2 in ovarian cancer
    Shoji, Yutaka
    Chirumamilla, Sin
    Chandramouli, G. V. R.
    Risinger, John I.
    CANCER RESEARCH, 2010, 70
  • [6] Expression of epithelial splicing regulatory protein 1 and 2 in ovarian cancer
    Shoji, Yutaka
    Chirumamilla, Siri
    Chandramouli, G. V. R.
    Risinger, John I.
    CANCER RESEARCH, 2010, 70
  • [7] Alternative splicing in ovarian cancer
    Wei, Liwei
    Li, Yisheng
    Chen, Jiawang
    Wang, Yuanmei
    Wu, Jianmin
    Yang, Huanming
    Zhang, Yi
    CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [8] The Role of RNA Splicing Factors in Cancer: Regulation of Viral and Human Gene Expression in Human Papillomavirus-Related Cervical Cancer
    Cerasuolo, Andrea
    Buonaguro, Luigi
    Buonaguro, Franco M.
    Tornesello, Maria Lina
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [9] Expression and alternative splicing of cyclin I mRNA in ovarian cancer and normal tissues
    Charoenvilaisiri, Saengsoon T.
    CANCER RESEARCH, 2006, 66 (08)
  • [10] Overview of splicing variation in ovarian cancer
    Zhou, Min
    Tian, Mengdie
    Li, Zhuoer
    Wang, Chunli
    Guo, Zhiqiang
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2025, 1880 (02):